Ember burns bright for Angle
A clinical hit could allow the group’s liquid biopsy to expand from breast cancer to ovarian.
Esmo 2022 – Galleri’s real-world exhibition disappoints
Grail finds the path for its liquid biopsy less clear than it might have hoped.
Freenome aims to take on the big beasts
Forthcoming data in colorectal cancer screening could put the company’s liquid biopsy on the market – but it looks like Guardant might get there first.
Medtech gears up for a vintage acquisition year
Device deal making is back in a big way, despite the munificence of venture funds.
